These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4601671)

  • 1. Toxicity study of BCNU (NSC-409962) given orally.
    Lessner HE; Vogler WR
    Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
    [No Abstract]   [Full Text] [Related]  

  • 2. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
    Rege VB; Owens AH
    Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
    [No Abstract]   [Full Text] [Related]  

  • 3. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of four-drug BCNU combination chemotherapy regimens.
    Durant JR; Lessner HE
    Cancer; 1973 Aug; 32(2):277-85. PubMed ID: 4722913
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy of advanced gastrointestinal cancer with the nitrosoureas.
    Moertel CG
    Cancer Chemother Rep 3; 1973 May; 4(3):27-34. PubMed ID: 4748872
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
    Tormey DC; Gailani S; Leone L
    Oncology; 1974; 29(3):244-8. PubMed ID: 4415043
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
    Robustelli della Cuna G; Paoletti P; Bernardo G; Knerich R; Butti G; Cuzzoni Q
    Neurosurgery; 1982 Sep; 11(3):408-11. PubMed ID: 6290930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of hexamethylmelamine (NSC 13875).
    Wilson WL; Schroeder JM; Bisel HF; Mrazek R; Hummel RP
    Cancer; 1969 Jan; 23(1):132-6. PubMed ID: 5812585
    [No Abstract]   [Full Text] [Related]  

  • 10. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
    Anderson T; DeVita T; Young RC
    Cancer Treat Rep; 1976 Jun; 60(6):761-7. PubMed ID: 782698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 12. [Preventive and therapeutic measures in cytostatic-associated toxicity].
    Cerny T; Buser K; Kiser J; Joss RA
    Schweiz Med Wochenschr; 1990 Sep; 120(37):1353-62. PubMed ID: 2218458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
    Fewer D; Wilson CB; Boldrey EB; Enot KJ; Powell MR
    JAMA; 1972 Oct; 222(5):549-52. PubMed ID: 4343318
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Marsh JC; DeConti RC; Hubbard SP
    Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs.
    Schein P; Anderson T
    Int J Clin Pharmacol; 1973 Nov; 8(3):228-38. PubMed ID: 4203921
    [No Abstract]   [Full Text] [Related]  

  • 16. Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Bonnet JD; Brownlee RW; Vaitkevicius VK; Talley RW
    Cancer Chemother Rep; 1973 Apr; 57(2):231-4. PubMed ID: 4742501
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
    Ahmann DL; Carr DT; Coles DT; Hahn RG
    Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of nonsteroidal anti-inflammatory drugs.
    Med Lett Drugs Ther; 1983 Feb; 25(628):15-6. PubMed ID: 6823224
    [No Abstract]   [Full Text] [Related]  

  • 19. Aminoglutethimide-induced hematologic toxicity: worldwide experience.
    Messeih AA; Lipton A; Santen RJ; Harvey HA; Boucher AE; Murray R; Ragaz J; Buzdar AU; Nagel GA; Henderson IC
    Cancer Treat Rep; 1985 Sep; 69(9):1003-4. PubMed ID: 4028032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone.
    Harrison DT; Neiman PE
    Cancer Treat Rep; 1977 Aug; 61(5):789-95. PubMed ID: 329978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.